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Gregg C. Fonarow, MD, FAHA, FACC; Willie Lawrence, MD, FAHA, FACC;
Kim A. Williams, MD, FAHA, FACC; Eduardo Sanchez, MD, MPHC ardiovascular diseases, including heart disease,hypertension, and heart failure, along with stroke,continue to be leading causes of death in the
United States (1,2). Hypertension currently affects nearly
78 million* adults in the United States and is also a major
modiﬁable risk factor for other cardiovascular diseases and
stroke (1). According to data from the National Health
and Nutrition Evaluation Survey (NHANES) in 2007 to
2010, 81.5% of those with hypertension are aware they
have it, and 74.9% are being treated, but only 52.5% are
under control, with signiﬁcant variation across different
patient subgroups (1,4–7). Of those with uncontrolled
hypertension, 89.4% reported having a usual source of
health care, and 85.2% reported having health insurance
(3). This is the current status, despite the fact that therapies
to lower blood pressure and associated risks of cardiovas-
cular events and death have been available for decades, and
various education and quality improvement efforts have
been targeted at patients and healthcare providers.
The direct and indirect costs of hypertension are enormous,
considering the number of patients and their families impacted,
and the healthcare dollars spent on treatment and blood pressure-
related complications (8). Currently, hypertension affects 46%
of patients with known cardiovascular disease and 72% ofqHypertension is published on behalf of the American Heart Association, Inc.,
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(1). In 2008, the total estimated direct and indirect cost of hy-
pertension was estimated at $69.9 billion (8). Thus, it is imper-
ative to identify, disseminate, and implement more effective
approaches to achieve optimal control of this condition.
High-quality blood pressure management is multifactorial
and requires the engagement of patients, families, providers,
and healthcare delivery systems and communities. This in-
cludes expanding patient and healthcare provider awareness,
appropriate lifestyle modiﬁcations, access to care, evidence-
based treatment, a high level of medication adherence, and
adequate follow-up (9). Recognizing the urgent need to address
inadequate control, the American Heart Association (AHA)
has made hypertension a primary focus area of its 2014 to 2017
strategic plan, because it seeks to improve the cardiovascular
health of all Americans by 20% and reduce the death rate from
cardiovascular disease and stroke by 20% by 2020 (10).
Similarly, Million Hearts, a U.S. Department of Health and
Human Services initiative spearheaded by the Centers for
Disease Control and Prevention (CDC) and the Centers for
Medicare & Medicaid Services to prevent a million heart
attacks and strokes by 2017, has focused its ﬁrst 2 years on
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1231We believe that the identiﬁcation of best practice,
evidence-based management algorithms leading to standard-
ization of treatment is a critical element in helping to achieve
these ambitious national goals at a population level. In this
article, we describe the value of hypertension treatment al-
gorithms, provide criteria for effective hypertension man-
agement algorithms, describe an AHA/American College of
Cardiology (ACC)/CDC-recommended treatment algorithm
based on current guidelines, and describe examples of other
speciﬁc algorithms that have been associated with improved
blood pressure on a large scale.The Value of Hypertension Treatment
Algorithms as Part of a Multifactorial
Approach to ImproveBloodPressureControl
As described previously, despite the strong evidence and
consensus regarding the treatment and control of high blood
pressure (9,12), as well as the availability of many different
therapeutic options, achieving success in hypertension control
at both the individual patient level and, even more impor-
tantly, the population level, has remained a major challenge
nationally.
Although there is no single explanation for the poor hy-
pertension control seen in many patient subgroups, the frag-
mentation of health care for many patients and the lack of
consistent implementation of system-level solutions in clinical
practice and healthcare delivery systems appear to be
important contributors. Efforts focused primarily on educating
patients and providers about hypertension and the beneﬁts of
its treatment have not been sufﬁcient in bringing hypertension
under control. Similarly, interventions targeting only physi-
cians have not led to consistent and meaningful improvements
on a large scale (13). However, there are examples of sub-
stantial success that could be emulated and scaled with a high
likelihood of important beneﬁt.
To reduce the prevalence of hypertension in the United
States (10,14), system-level approaches will be needed. Suc-
cessful examples from other medical areas where a system-
level approach has been taken include reducing medical
errors and improving patient safety in the hospital setting
(15); improving the inpatient treatment and outcomes of
acute myocardial infarction, heart failure, stroke, and cardio-
pulmonary resuscitation (16); reducing health disparities in the
treatment of cardiovascular conditions (16); early detection
and intervention in sepsis to lower case fatality (17,18); and
reducing hospital-acquired infections (19,20). In the case of
hypertension, system-level methods can address multiple
factors in a coordinated manner:
 Identifying all patients eligible for management
 Monitoring at the practice/population level
 Increasing patient and provider awareness
 Providing an effective diagnosis and treatment guideline Systematic follow-up of patients for the initiation and
intensiﬁcation of therapy
 Clarifying roles of healthcare providers to implement a
team approach
 Reducing barriers for patients to receive and adhere to
medications and to implement lifestyle modiﬁcations
 Leveraging the electronic medical record systems being
established throughout the United States to support each
of these steps
Several examples of success with the use of a system-level
paradigm have been recently reported. For example, within
Kaiser Permanente Northern California, a large integrated
healthcare delivery system caring for >3 million members, a
regional hypertension program was implemented involving
5 major components: creation and maintenance of a health
system-wide electronic hypertension registry, tracking hy-
pertension control rates with regular feedback to providers at a
facility and provider level, development and frequent updat-
ing of an evidence-based treatment guideline, promotion of
single-pill combination therapies, and using medical assistants
for follow-up blood pressure checks to facilitate necessary
treatment intensiﬁcation. Between 2001 and 2009, the number
of patients with hypertension increased from 349,937 to
652,763, but the proportion of hypertensive patients meeting
target blood pressure goals improved substantially from
44% to >80%, and continued to improve to >87% in 2011
(21). Favorable hypertension control rates have been observed
in other healthcare delivery systems (22), as well as in coor-
dinated health systems such as the Veterans Affairs medical
system (23–25).
Developing, disseminating, and implementing an effective
hypertension treatment algorithm is a critical part of a
multipronged, systematic approach to controlling hyperten-
sion, because it facilitates clinical decision making, provides a
default approach with proven beneﬁts, and engages multiple
providers in a coordinated manner. We describe next the
principles for developing such an algorithm.Principles for Algorithm Development
The following is a summary of principles recommended by
the AHA, ACC, and CDC for creating an effective hyper-
tension management algorithm:
1. Base algorithm components and processes on the best
available science
2. Format to be simple to update as better information
becomes available
3. Create feasible, simple implementation strategy
4. Include patient version at appropriate scientiﬁc and
language literacy level
5. Consider costs of diagnosis, monitoring, and treatment
6. Develop algorithm in format easily used within a team
approach to health care
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12327. Develop algorithm in a format able to be incorporated
into electronic health records for use as clinical deci-
sion support
8. Include a disclaimer to ensure that the algorithm is not
used to counter the treating healthcare provider’s best
clinical judgment
The purpose of these principles is to establish a common
platform for the development and implementation of hyper-
tension management algorithms tailored to different practice
settings and populations. We note that the last principle
supports the notion that treatment guidelines serve to facilitate
a systematic approach to the management of hypertension, but
provide appropriate modiﬁcations based on speciﬁc patient
characteristics, preferences, and other pragmatic factors (e.g.,
cost, pill burden, risks of certain side effects) to optimize a
personalized approach to the care of individual patients
(9,12,26,27). In addition, ongoing randomized clinical trials
(e.g., Systolic Blood Pressure Intervention Trial [SPRINT])
(28) are addressing optimal blood pressure targets for speciﬁc
patient subgroups such as the elderly and patients with
chronic kidney disease to maximize net clinical beneﬁt and
avoid unnecessary complications.
AHA/ACC/CDC
Hypertension Treatment Algorithm
In the Appendix is a template outlining a general approach for
an effective treatment algorithm that incorporates the princi-
ples described previously and balances applicability to the
largest number of hypertensive patients with the ﬂexibility
and the level of detail to support individualization of therapy.
Several existing algorithms for hypertension treatment in
large healthcare settings associated with improved blood
pressure in populations (21) have also been reviewed, which
included a look at both private and public systems, systems
with regional reach, and an algorithm used by the US
Department of Veterans Affairs, that are in support of the
recommended principles. These algorithms can either be
found in the online-only Data Supplement or are available for
public use within the resources and tools section of the
Million Hearts initiative Web site at http://millionhearts.hhs.
gov/resources.html.
Call-to-Action, Next Steps,
and Conclusions
It is critical that the AHA, ACC, and CDC, together with
other organizations, continue to identify, deﬁne, and imple-
ment exemplary local, regional, and national programs that
facilitate better blood pressure awareness, treatment, and
control together with improving other cardiovascular health
factors and behaviors (11,15,29–32). Arming healthcare pro-
viders, health systems, and communities with proven tools,
algorithms, strategies, programs, and other best practicesalong with expertise and technical assistance for improving
blood pressure awareness, treatment, and control is essential
to reducing the tremendous burden of cardiovascular risk
(30,33).
This advisory serves as a call to action for broad-based
efforts to improve hypertension awareness, treatment, and
the proportion of patients treated and controlled. There is a
clear need to provide enhanced, evidence-based, blood pres-
sure treatment systems for providers, including the standard-
ization of protocols and algorithms, incentives for improved
performance based on achieving and maintaining patients at
blood pressure goals, and technology-facilitated clinical de-
cision support and feedback (34). As noted previously, health
system–wide implementation of focused evidence-based hy-
pertension treatment algorithms together with regularly
scheduled performance feedback within a coordinated multi-
factorial management program have been associated with
substantially improved hypertension control in large pop-
ulations and varied clinical practice settings (21,33–35). This
approach can facilitate the ability to emphasize existing
evidence-based recommendations and integrate new evidence
as it becomes available. Successful best practices or in-
novations can be further identiﬁed and then disseminated health
system wide (21). Such an approach is scalable, sustainable,
and of high value, especially as the use of electronic medical
records becomes even more widespread nationally (21,34–36).
This advisory has provided a number of examples of algo-
rithms from successful programs that can be readily imple-
mented in diverse healthcare settings. Greater participation in
innovative programs such as the AHA’s Heart 360 personal
health record (37), AHA/American Stroke Association’s
Get With The Guidelines Program (38), the AHA/American
Diabetes Association/American Cancer Society Guideline
Advantage Program (39), the U.S. Department of Health and
Human Services Million Hearts initiative (11,15,30,31),
ACC’s National Cardiovascular Data Registries (40), and the
CDCCoverdell Stroke registry (41) should also be encouraged
and incentivized.
Further engaging individuals in the hypertension control
process, motivating more proactive management through
shared accountability, and incentives for blood pressure treat-
ment and control are also essential (30). There are also oppor-
tunities for the increased role of pharmacists and other
community-based providers in hypertension treatment and
control (30,36,42). There is also great potential to apply an
innovative mix of health information technology, peer
support, feedback, and incentive programs designed to drive
actionable, patient-centered blood pressure awareness, treat-
ment, and control programs. Workplace and community-based
wellness programs can also have signiﬁcant impact (30).
It is also vital that these programs are implemented among
broader segments of the population. Disparities/inequities
in hypertension awareness, treatment, and control continue to
exist in a number of patient subgroups (7,43). Intervention
programs for hypertension should be speciﬁcally targeted to
groups with the greatest cardiovascular risk and disease burden
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1233based on clinical risk factors and appropriate consideration of
sex, race, ethnicity, socioeconomic status, disability, and
geographic location (30). Additional research is needed to
better deﬁne blood pressure treatment goals, especially in
speciﬁc populations, including by age, sex, race, ethnicity, and
comorbid conditions. It is also essential that there be adequate
representation of these patient populations in the study of
optimal blood pressure goals, as well as new hypertension
treatment technologies (e.g., catheter-based renal sympathetic
denervation).
The AHA, ACC, CDC, and other organizations should
continue to foster effective activities regarding hypertension
that include surveillance, education and media, organizational
partnerships, and environmental and policy changes (30).
Building on such programs as the
 AHA’s Life’s Simple 7 program (44), with a longitu-
dinal cardiovascular health tracking system, patient-
oriented clinical decision support tool, individual
patient-oriented cardiovascular health performance
measures, and data feedback, and
 ACC’s CardioSmart Patient Education Portal (45), with
a customized patient dashboard for blood pressure
management, an interactive workbook to educate and
motivate better health, and a patient text messagingprogram providing heart healthy tips aimed at primary
prevention
should be considered within a comprehensive system-level
management program. This approach may help to facilitate
and incentivize improvement in blood pressure control and
cardiovascular health, as well as enhance real-time surveil-
lance of cardiovascular health. Further research efforts to
enhance speciﬁc interventions for improving patient adher-
ence and to identify optimal patient-centered, value-oriented
systems of care should continue to be supported.
This advisory is intended to complement and support
clinical guidelines, providing clinicians and health systems
tools to improve the treatment and control of hypertension.
The prevention of heart disease and stroke mandates a greater
emphasis on the population-wide improvement of blood
pressure awareness, treatment, and control together with other
cardiovascular health factors (15,26,46).Appendix
Controlling hypertension in adults (see next pages for the
treatment algorithm).
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